Source: Contract Pharma

Fujifilm Irvine Scientific: FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform for Bioprocessing

Adds specific media to support DG44 cell lines and perfusion culture platforms for the commercialization of mAbs, recombinant proteins and other biotherapeutics

Read full article »
Fujifilm Irvine Scientific's Competitors | Fujifilm Irvine Scientific's News | Fujifilm Irvine Scientific's Financials
Stay up-to-date with the latest news on Fujifilm Irvine Scientific
Est. Annual Revenue
$5.0-25M
Est. Employees
250-500
Yutaka Yamaguchi's photo - President & CEO of Fujifilm Irvine Scientific

President & CEO

Yutaka Yamaguchi

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on Fujifilm Irvine Scientific